FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53  by Ochocka, Anna Maria et al.
FEBS Letters 583 (2009) 621–626journal homepage: www.FEBSLetters .orgFKBP25, a novel regulator of the p53 pathway, induces the degradation
of MDM2 and activation of p53
Anna Maria Ochocka a, Petros Kampanis a, Samantha Nicol b, Nerea Allende-Vega b, Miranda Cox a,
Lynnette Marcar a, Diane Milne a, Frances Fuller-Pace b, David Meek a,*
aBiomedical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Level 5, University of Dundee, Dundee DD1 9SY, United Kingdom
bCentre of Oncology and Molecular Medicine, Ninewells Hospital and Medical School, University of Dundee, Level 6, University of Dundee, Dundee DD1 9SY, United Kingdoma r t i c l e i n f o
Article history:
Received 5 November 2008
Revised 17 December 2008
Accepted 11 January 2009
Available online 21 January 2009
Edited by Angel Nebreda
Keywords:
FKBP25
MDM2
p53
E3 ligase
Ubiquitylation
Degradation0014-5793/$34.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.01.009
Abbreviations: MDM2, mouse double minute 2; FK
protein; PPI, peptidyl-prolyl isomerase
* Corresponding author. Fax: +44 1382 669993.
E-mail address: d.w.meek@dundee.ac.uk (D. Meeka b s t r a c t
The p53 tumour suppressor protein is tightly controlled by the E3 ubiquitin ligase, mouse double
minute 2 (MDM2), but maintains MDM2 expression as part of a negative feedback loop. We have
identiﬁed the immunophilin, 25 kDa FK506-binding protein (FKBP25), previously shown to be reg-
ulated by p53-mediated repression, as an MDM2-interacting partner. We show that FKBP25 stimu-
lates auto-ubiquitylation and proteasomal degradation of MDM2, leading to the induction of p53.
Depletion of FKBP25 by siRNA leads to increased levels of MDM2 and a corresponding reduction
in p53 and p21 levels. These data are consistent with the idea that FKBP25 contributes to regulation
of the p53-MDM2 negative feedback loop.
Structured summary:
MINT-6823686: MDM2 (uniprotkb:Q00987) physically interacts (MI:0218) with FKBP25 (uni-
protkb:Q00688) by anti bait coimmunoprecipitation (MI:0006)
MINT-6823707, MINT-6823722: MDM2 (uniprotkb:Q00987) physically interacts (MI:0218) with FKBP25
(uniprotkb:Q62446) by pull down (MI:0096)
MINT-6823775: P53 (uniprotkb:Q04637) physically interacts (MI:0218) with MDM2 (uniprotkb:Q00987)
by anti bait coimmunoprecipitation (MI:0006)
MINT-6823735, MINT-6823749: FKBP25 (uniprotkb:Q62446) binds (MI:0407) to MDM2 (uni-
protkb:Q00987) by pull down (MI:0096)
MINT-6823761: Ubiquitin (UNIPROTKB:62988) physically interacts (MI:0218) with MDM2 (uni-
protkb:Q00987) by pull down (MI:0096)
MINT-6823669: MDM2 (uniprotkb:Q00987) physically interacts (MI:0218) with FKBP25 (uni-
protkb:Q00688) by two hybrid (MI:0018)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction in [2].) p53 and mouse double minute 2 (MDM2) form an autoreg-The p53 tumour suppressor protein is a short-lived transcrip-
tion factor that is induced in response to a wide variety of cellular
stresses including DNA damage and hyper-proliferation (reviewed
in [1].) Activated p53 orchestrates the transactivation or transre-
pression of many target genes leading to growth arrest, senescence
or apoptosis. p53 is regulated mainly by the oncoprotein MDM2, a
RING ﬁnger-containing E3 ubiquitin ligase that mediates its ubiq-
uitylation and rapid proteasome-dependent degradation (reviewedchemical Societies. Published by E
BP25, 25 kDa FK506-binding
).ulatory loop in which p53 positively regulates MDM2 expression
while MDM2 negatively regulates p53 levels and activity. Cellular
stresses that induce p53 disrupt the p53-MDM2 interaction with
the effect of attenuating p53 degradation and stimulating MDM2
auto-ubiquitylation and degradation [1].
The immunophilin, FKBP25 (also known as FKBP3), is a nuclear
DNA-binding protein that encompasses peptidylprolyl cis–trans
isomerase (PPI) activity ([3] and references therein). The FKBP25
protein comprises a conserved FK506/rapamycin binding domain
at its C-terminus and a unique multi-functional hydrophilic N-ter-
minal region containing a helix-loop-helix motif. FKBP25 has an
established role in regulating gene expression [4] and associates
with several signalling molecules including protein kinase CK2 [3]
and histone deacetylases HDAC-1 and -2 [4]. Interestingly, expres-
sion of FKBP25 itself is repressed in a p53-dependent manner [5].lsevier B.V. All rights reserved.
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interacting protein that can decrease MDM2 levels by stimulating
the ability of MDM2 to undergo auto-ubiquitylation. These ﬁnd-
ings suggest that FKBP25 can regulate the p53-MDM2 regulatory
negative feedback loop.
2. Materials and methods
2.1. Plasmids
A cDNA encoding human FKBP25 (obtained from Geneservice
Ltd.) was cloned in the pSG5 (Stratagene) derivative, pSG9M,
linked through its 50 region and in frame with an oligonucleotide
encoding the Myc 9E10 epitope. Human p53 (wild type or mutant)
and MDM2 were cloned in the vector pcDNA3 (Invitrogen) for
mammalian cell expression. GST-fusion proteins were expressed
in Escherichia coli using pGEX vectors and puriﬁed on glutathi-
one-sepharose 4B beads according to the manufacturer’s instruc-
tions (GE Healthcare). Deletion derivatives of the above plasmids
were generated using the Stratagene QuikChange site-directed
mutagenesis system.
2.2. Yeast two-hybrid analysis
Yeast two-hybrid analysis was carried out using the Clontech
GAL4 Matchmaker system as instructed by the manufacturer
(Clontech). A cDNA encoding amino acids 108–207 of human
MDM2 was cloned in pGBTK7 in frame to produce a GAL4
DNA-binding domain fusion protein. The yeast strain Y190 was
transformed with the pGBTK-MDM2 DNA and assayed for
b-galactosidase activity to conﬁrm that this region of MDM2 did
not have autonomous transactivating activity. The pGBTK7-
MDM2 Y190 strain was then transformed with a human testis
cDNA library fused to the GAL4 activation domain in the pACT2
vector (Clontech) to screen for MDM2-interacting proteins. A total
of 5  106 colonies were screened and 48 independent His+
b-galactosidase-positive clones, which had been selected on
45 mM 3-amino-1,2,4-triazole (3-AT) to minimise the His back-
ground, were analysed by PCR using suitable primers from the
pACT2 vector sequence to amplify inserts, and sequenced. The
NCBI database was searched for homologous sequences using
BLAST search. False positives were eliminated by (a) discarding
those which did not contain open reading frames in frame with
the transactivation domain, and (b) cotransforming putative posi-
tive clones with a control bait plasmid (pAS2-lamin; Clontech)
and showing that they do not interact in this system.
2.3. Cell culture and transfection
This study employed H1299 (p53-null lung carcinoma-derived),
MCF-7 (wild type p53-positive breast carcinoma-derived), U2OS
(wild type p53-positive osteocarcinoma-derived) and HCT116
(p53/ and p53 +/+) cells. DNA transfections were carried out
using lipofectamine2000, or Fugene (Roche), each according to
the manufacturer’s instructions.
2.4. Antibodies
Monoclonal antibodies D12 and SMP14 (anti-MDM2), DO1 and
PAb1801 (both anti-p53) and RK5C1 (anti-GAL4) were obtained
from Santa Cruz Biotechnology. 4B2 (anti-MDM2 [6]) was a kind
gift from Prof Sir David Lane (Dundee). Monoclonal antibodies
9E10 (anti-c-Myc) and 4G12 (anti-acetylated lysine) were from
Cancer Research UK and Millipore respectively. Polyclonal antibod-
ies were used against p21 (sc-756; Santa Cruz Biotechnology),
FKBP25 (ab16654; Abcam) and actin (A5060; Sigma–Aldrich).2.5. Immunoprecipitation and western blotting
Standard procedures for immunoprecipitation and western
blotting have been described elsewhere [7].
2.6. GST-pulldown experiments
GST-MDM2 or GST-FKBP25 fusion proteins were expressed in
E. coli as described above and immobilised on glutathione-sephar-
ose 4B beads using standard conditions. GST-pulldowns experi-
ments were performed as described elsewhere [7].
2.7. Luciferase assays
Luciferase assays were carried out essentially as described in
[8].
2.8. In vivo ubiquitylation assay
This assay has been described in signiﬁcant detail elsewhere [9].
2.9. siRNA
Experiments were performed in 6-well plates with a total of
2.5  105 cells/well. Cells were transfected using Lipofectamine
RNAiMAX (Invitrogen) with two independent siRNA oligonucleo-
tides (ﬁnal concentration 60 nM) targetted against FKBP25 or, as
control, a non-targeted oligonucleotide (Dharmacon). Cells were
grown for 48 h and if necessary the procedure was repeated. Cells
were harvested after 48 or 96 h. The sequence of the non-targetted
siRNA oligonucleotide is: 50 CAGUCGCGUUUGCGACUGGUU 30. The
FKBP25 ‘‘ON-TARGETplus” siRNA oligonucleotides (Catalogue Nos.
J-009568-06 and J-009568-07). The sequences are, respectively:
siRNA1, 50 UAAAGUGUCUGAGCAAGUAUU 30 and siRNA2, 50 GGAU-
GAAGCUCUCUUGACUUU 30.
3. Results and discussion
3.1. Isolation of FKBP25 as an MDM2-interacting protein
To search for partner proteins that interact with MDM2, a
cDNA encoding amino acids 108–207 of human MDM2 was cloned
into the yeast expression vector pGBKT7 and used as bait in the
yeast two-hybrid system. The resultant plasmid expressed a
GAL4(DNA-binding domain)-MDM2 fusion protein of approxi-
mately 55 kDa in Y190 yeast cells (data not shown). The bait
protein alone did not induce expression of the LacZ reporter gene
in the Y190 cells (data not shown).
Y190 cells harbouring the pGBKT7-MDM2 plasmid were
transformed with a human testis cDNA library. A total of 5  106
colonies were screened and 48 independent His+ b-galactosidase-
positive clones were analysed. False positives were eliminated as
described under Section 2. Using this approach a clone (designated
clone 40) was obtained which had 100% homology to the C-termi-
nal 90 amino acids of the human FKBP25 gene (Fig. 1A). Interest-
ingly, a potential link between FKBP25 and the p53 pathway had
previously been inferred from the ﬁnding that FKBP25 expression
is repressed by p53 [5].
3.2. MDM2 and FKBP25 interact in vitro and in mammalian cells
Analysis of the interaction of MDM2 and FKBP25 in vitro and in
mammalian cells was undertaken using a murine FKBP25 cDNA.
(The murine and human proteins share 95% identity and 99% sim-
ilarity). In vitro GST-pull-down assays, in which immobilised GST-
MDM2 was incubated with extracts expressing Myc(9E10)-tagged
Fig. 1. Interaction of FKBP25 with MDM2 in vitro and in cultured cells. (A) The
FKBP25 protein is shown schematically. The C-terminal region encoded within
clone 40 is indicated. (B) Bacterially expressed fusion proteins comprising GST-
MDM2, GST-FKBP25 or, as control, GST alone were bound to glutathione-sepharose
4B beads and subsequently incubated with extracts of H1299 cells that had been
transiently transfected with plasmids expressing MDM2 or FKBP25. Immobilised
proteins were detected by western blotting. The input represents 10% of the
material used in the pull-down. (C) Immunoprecipitations of endogenous proteins
were performed on U2OS and H1299 cell extracts using antibodies speciﬁc for
MDM2 (D12/SMP14), p53 (PAb1801/DO1), GAL4 (as control, RK5C1) and FKBP25
(polyclonal antisera). Co-immunoprecipitating proteins were detected by western
blotting as indicated. The arrow shows the position of FKBP25 while the asterisk
indicates a non-speciﬁc signal obtained with the p53 immunoprecipitations
(present even in the immunoprecipitation from the p53-null H1299 cells). The
input represents 10% of the material used in the immunoprecipitation.
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can associate in vitro (Fig. 1B). In the reciprocal pull-down experi-
ment immobilised GST-FKBP25 was shown to interact with MDM2
(Fig. 1B).
Endogenous FKBP25 was observed to co-immunoprecipitate
with endogenous MDM2, but not with p53 or in a control immuno-
precipitation (Fig. 1C). These data are consistent with the idea that
MDM2 and FKBP25 proteins can interact physiologically and spe-
ciﬁcally. When reciprocal analysis was carried out, MDM2 didnot co-immunoprecipitate with FKBP25 (Fig. 1C). The most plausi-
ble explanation for this result is that the immunoprecipitating
FKBP25 (polyclonal) antibody may disrupt the association between
the two proteins. Immunoﬂuorescence analysis indicated that
FKBP25 is mainly cytoplasmic, but a proportion is present in the
nucleus together with MDM2 (Supplementary Fig. 1). Treatment
with the CRM1 (nuclear export) inhibitor, leptomycin B (LMB),
indicated that FKBP25 can shuttle between the nucleus and cyto-
plasm (Supplementary Fig. 2).
GST-pulldown experiments (Supplementary Fig. 3) using a ser-
ies of FKBP25 deletion derivatives highlighted a strong region of
interaction between MDM2 and the C-terminal portion of FKBP25
(within amino acids 133–224 [lane 8], the region encoded by clone
40 in the yeast two-hybrid system [see above].) Weaker binding to
MDM2 was also observed with the regions encompassing amino
acids 43–110 and 110–133. Amino acids 1–42 of FKBP25 did not
bind to MDM2 (lane 4). In all cases the binding of the fragments
of FKBP25 to MDM2 was weaker than that observed with full
length FKBP25. These data are consistent with the idea that
MDM2 binds preferentially to intact FKBP25, possibly through
multiple contacts. It should be noted, however, that protein/pro-
tein interactions often occur through the association of structured
domains from each protein. We cannot therefore rule out the pos-
sibility that the low degree of binding observed with the deletion
mutants of FKBP25 may actually reﬂect a loss of domain structure.
Additionally, these proteins may fold up less efﬁciently in the envi-
ronment of an E. coli cell as compared with the natural mammalian
cell environment.
When full length MDM2 and a series of MDM2 deletion deriva-
tives, as GST-fusion proteins, were used to assess interaction with
in vitro-transcribed/translated FKBP25, only the full length MDM2
was able to associate detectably with FKBP25 in the pull-down
experiments (data not shown; the overlapping regions of MDM2
in these fusion proteins comprised amino acids 1–110, 108–207,
203–282 and 279–491). Therefore, while the yeast two-hybrid
system displayed sufﬁcient sensitivity to reveal an interaction bet-
ween FKBP25 and amino acids 108–207 of MDM2, this particular
interaction was not robust enough to be detected in the pull-down
system. These data again suggest that optimal interaction with
FKBP25 may be mediated by multiple contacts.
3.3. FKBP25 stimulates proteasome-dependent down-regulation of
MDM2
To determine whether FKBP25 could inﬂuence the interaction
between MDM2 and p53, H1299 cells were transfected with plas-
mids encoding p53, MDM2 and Myc-tagged FKBP25. Western anal-
ysis of the cell extracts revealed the striking observation that the
levels of MDM2 were depleted signiﬁcantly when co-expressed
with FKBP25 (Fig. 2A). Additionally, a ladder of slower migrating
p53 bands was absent in the cells expressing FKBP25 (Fig. 2A).
Based on previous work (e.g. see Ref. [10]), these bands most likely
represent ubiquitylated forms of p53. Incrementally increased
expression of the FKBP25-expressing plasmid led to a decrease in
MDM2 levels and a corresponding increase in p53 levels
(Fig. 2B). Consistent with this observation, increased FKBP25
expression led to proportional increases in p53 transactivation
function that were seen only with wild type p53, but not with a
transcriptionally defective mutant (Fig. 2C). Interestingly, the
reduction in MDM2 levels mediated by FKBP25 could be rescued
by treating the cells with the proteasomal inhibitor, MG132, sug-
gesting that FKBP25 may regulate MDM2 destruction (Fig. 2D).
When full length FKBP25 and a series of deletion derivatives
were compared for their ability to reduce MDM2 levels, deletion
of all or parts of the C-terminal (110–224) or the N-terminal
(1–110) domains led to a loss of FKBP25 function (Fig. 3). These
Fig. 2. FKBP25 stimulates proteasomal degradation of MDM2 leading to increased
p53 levels and activity. (A) H1299 cells (MDM2-competent, p53-null) were
transfected with plasmids expressing p53 (25 ng), MDM2 (2 lg) and Myc (9E10)-
tagged FKBP25 (3 lg), as indicated on the panel. Cell extracts were analysed by
western blotting as indicated. (B) H1299 cells were transfected with plasmids
expressing p53 (10 ng) with or without MDM2 (1 lg), and in the absence or
presence of increasing amounts of a plasmid expressing Myc(9E10)-tagged FKBP25.
Cell extracts were analysed for the levels of p53, MDM2 and FKBP25. (C) H1299
cells were transfected in six-well plates with a reporter plasmid comprising the
luciferase gene under control of the p53-inducible PG13 promoter. Myc-FKBP25
together with wild type p53 or the L22Q/W23S transcriptionally-inactive mutant of
p53 was co-expressed as indicated. (D) H1299 cells were transfected with plasmids
expressing MDM2 (2 lg), with or without a plasmid expressing Myc (9E10)-tagged
FKBP25 (3 lg), and in the presence or absence of MG132 (20 lM) as indicated.
Fig. 3. Efﬁcient down-regulation of MDM2 requires full-length FKBP25. (A)
Schematic representation of the FKBP25 deletion mutants used in the experiment
in panel B. (B) H1299 cells were transfected with plasmids encoding MDM2
together with plasmids encoding full length FKBP25 or a series of deletion
derivatives of FKBP25. Cell extracts were prepared 48 h after transfection and
analysed by western blotting using the antibodies 4B2/SMP14 (MDM2), 9E10 (Myc-
FKBP25) and A5060 (actin).
Fig. 4. FKBP25 stimulates auto-ubiquitylation of MDM2. (A) H1299 cells were
transfected with plasmids expressing His-tagged ubiquitin (5 lg) and MDM2 (5 lg)
together with increasing amounts (5 or 10 lg) of the Myc-tagged FKBP25-
expressing plasmid. Cells were lysed in guanidinium-containing buffer [9] after
which the ubiquitylated proteins were puriﬁed on Ni2+-NTA-agarose beads and
analysed by Western blotting (upper panel). The presence of total MDM2, FKBP25
and actin in the unpuriﬁed lysates was detected by western blotting (lower three
panels). (B) H1299 cells were transfected with plasmids encoding wild type MDM2,
a C464A ubiquitylation-defective mutant of MDM2, and/or Myc-tagged FKBP25.
Forty-eight hours after transfection, cell extracts were prepared and analysed by
Western blotting using the antibodies 4B2/SMP14 (MDM2), 9E10 (Myc-FKBP25)
and A5060 (actin).
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cient decrease in MDM2 levels.
3.4. FKBP25 promotes auto-ubiquitylation of MDM2
To understand the mechanism by which FKBP25 promotes
MDM2 degradation, the possibility that FKBP25 could inﬂuence
MDM2 auto-ubiquitylation was examined using a cell-based
ubiquitylation assay [9]. As before, increasing levels of FKBP25
led to a decrease in the levels of MDM2 (Fig. 4A, middle panel).
Notably, FKBP25 stimulated the ubiquitylation of MDM2 in a
dose-dependent manner. To determine whether this ubiquitylation
required the ubiquitylation function of MDM2 itself (i.e was auto-
ubiquitylation), the ability of FKBP25 to down-regulate MDM2 was
examined using a RING ﬁnger domain mutant of MDM2 (C464A)
that is ubiquitylation-deﬁcient. Signiﬁcantly, while FKBP25 pro-
moted degradation of wild type MDM2 (in a manner that could
be rescued by MG132 treatment), it was unable to stimulate the
degradation of the C464A mutant (Fig. 4B). This observation under-
scores the conclusion that FKBP25 inﬂuences the ability of MDM2
to mediate its own destruction.
How FKBP25 achieves this end is unclear at present. One possi-
bility is that recruitment of CK2 by FKBP25 [3], a protein kinase that
phosphorylates and activates MDM2 [11], could stimulate MDM2
turnover. However, FKBP25-mediated degradation of MDM2 can
still occur in the presence of high levels of the CK2-speciﬁc inhibi-
tor, 4,5,6,7-tetrabromobenzotriazole (TBB; [12]), suggesting that
this mechanism is unlikely (Supplementary Fig. 4A). Another po-
tential mechanism is that by recruiting histone deacetylases
(HDAC-1 and -2) [4], FKBP25 could free up acetylated lysine resi-
dues in MDM2 [13] that would then be available for auto-ubiquity-lation. Yet again, however, this seems unlikely as we have been
unable to prevent degradation of MDM2 by FKBP25 using the HDAC
inhibitor, trichostatin A (TSA; Supplementary Fig. 4B). Another
possibility is that FKBP25 could displace the important deubiquity-
lating enzyme HAUSP fromMDM2 [14] but our analyses have so far
been unable to detect this (data not shown). Alternatively, FKBP25
may simply induce a conformational shift in MDM2 favouring its
auto-ubiquitylation perhaps through protein/protein contact or, in-
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MDM2 degradation by FKBP25 was, however, unaffected by rapa-
mycin (which inhibits PPI function) suggesting that it does not de-
pend on PPI activity (Supplementary Fig. 5).
3.5. Knock-down of endogenous FKBP25 leads to increased MDM2 and
reduced p53 levels
To determine whether alterations in the level of endogenous
FKBP25 could affect the endogenous p53 pathway, FKBP25 levels
were depleted by siRNA using two independent siRNA oligonucle-
otides. Since FKBP25 is a stable protein (e.g. see Fig. 2D), the cells
were harvested and examined 96 hours after the initial knock-
down. A representative set of data from this analysis is shown in
Fig. 5A, while the data from three separate experiments are aver-
aged as shown in Fig. 5B. Knock-down of FKBP25 using either oli-
gonucleotide resulted in an approximately 80% reduction in
FKBP25 protein levels and was accompanied by a notable increase
in MDM2 levels. Consistent with this result, p53 and p21 levels
were depleted by 40–50%. (Note that, since MDM2 itself is a p53-
responsive gene, the increase in MDM2 levels observed following
knock-down of FKBP25 may be dampened down by the reduction
in p53 levels.) A similar pattern was observed over the separate
experiments although some variability was seen, both in the extent
to which FKBP25 knock-down could be achieved and, accordingly,
in the degree of change in MDM2, p53 and p21. Nevertheless, these
data support the idea that changes in FKBP25 levels can have a
knock-on effect on p53 levels and signalling. When the analysis
was carried out following treatment of the cells with etoposide
to induce the p53 pathway (Fig. 5C and D), increased MDM2 levels
could still be observed but this had no effect on the p53 levels
(which were high following the induction), presumably because
DNA damage uncouples p53 from MDM2-mediated degradation.Fig. 5. Knock-down of endogenous FKBP25 leads to up-regulation of MDM2 and decreas
oligonucleotides targeted against FKBP25 or, as control, a non-targeted oligonucleotide, a
blotting using the antibodies 4B2/SMP14 (MDM2), DO1, (p53), sc-756 (p21) and A5060 (a
set of autoradiographs is shown in panel (A), while panel (B) shows the relative chang
experiment was carried out as in panel A except that the cells were treated for 6 h with
p53 and p21 over three separate experiments following etoposide treatment.3.6. FKBP25 and the p53 pathway
In the present study, we have identiﬁed the immunophilin,
FKBP25, as a potential regulator of MDM2 and, consequently, of
the p53 pathway. Our data indicate that FKBP25 can stimulate
the ability of MDM2 to undergo auto-ubiquitylation leading to its
rapid degradation (Fig. 4). Consistent with this idea, knock-down
of FKBP25 gives rise to increased levels of MDM2 leading to reduc-
tions in the levels of p53 and its downstream effector, p21 (Fig. 5).
These changes in MDM2, p53 and p21 levels are subtle and,
accordingly, we have not been able to observe any signiﬁcant effect
of the knock-down on p53-mediated cell cycle arrest (data not
shown) presumably because we are working at the edge of resolu-
tion for achieving these changes. A more deﬁnitive assessment of
the effects of FKBP25 on the p53 response may therefore await
the availability of FKBP25 knock-out cells. We have also considered
the possiblity that, since FKBP25 is a member of a sub-family of
highly related proteins, there may be some redundancy and that
other members of the family may be able to prevent signiﬁcant
rises in MDM2 levels following loss of FKBP25.
Reversible induction of the p53 response has at least two
phases: in the ﬁrst few hours, MDM2 is rapidly destroyed, p53
accumulates and p53-mediated gene expression gets underway
[1]. In the second, later phase, MDM2, which is elevated in a
p53-dependent manner, becomes active and attenuates the
response [1]. FKBP25 mRNA levels were previously reported to be
repressed in a p53-responsive manner [5]; (our unpublished data
have conﬁrmed this observation, at least in some cell lines). How-
ever, the reported kinetics of FKBP25 repression are signiﬁcantly
slower than p21 induction [5]. This strongly suggests that any
effects of decreasing FKBP25 levels are likely to be felt after com-
pletion of the ﬁrst phase and may actually assist the attenuation
response by relieving (at least in part) negative regulation ofed levels of p53 and p21. MCF-7 cells were transfected with two independent siRNA
s described in Section 2. The cells were harvested after 96 h and analysed by western
ctin). FKBP25 was detected using a polyclonal antibody (ab16654; Abcam). A typical
es in the levels of MDM2, p53 and p21 over three separate experiments. (C) The
50 lM etoposide before harvesting. (D) The relative changes in the levels of MDM2,
626 A.M. Ochocka et al. / FEBS Letters 583 (2009) 621–626MDM2. p53 is involved in many feedback loops with its regulators
[15] and we would venture to suggest that such a reciprocal rela-
tionship between the p53 pathway and FKBP25 may add an addi-
tional level of sensitivity to maintaining p53 pathway homeostasis.
Our data support these ideas in principle but whether and how
they might operate physiologically, in what cells/tissues and under
what conditions they are most relevant, might best be addressed in
the context of an FKBP25 knock-out (or conditional knock-out)
mouse.
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